Day: March 18, 2024

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Written by Customer Service on March 18, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin”). Thomas Carey, Chairman of the Standard BioTools Board of Directors, said, “We are pleased to reach this agreement with Viking and Casdin. By streamlining our capital structure, we believe this transaction will make us more attractive to new long-term investors and potential M&A partners, as we pursue our strategy to unlock value for all of our stockholders in this highly fragmented market. We appreciate...

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer – Exploring New Laboratory Diagnostic Options

Written by Customer Service on March 18, 2024. Posted in Public Companies.

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024. Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening. Set against the backdrop of March’s Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection....

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

Written by Customer Service on March 18, 2024. Posted in Earnings Releases And Operating Results.

– FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study – CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives. Abeona also announced today that the U.S. Food and Drug Administration (FDA) has completed a Pre-License Inspection (PLI) of its Cleveland, Ohio manufacturing facility related to the Company’s Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB). During the inspection, the FDA reviewed the facilities, systems, and processes at the Cleveland site. The...

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Written by Customer Service on March 18, 2024. Posted in Public Companies.

Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression.WESTON, Fla., March 18, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces Institutional Review Board (IRB) approval of the Phase 2a clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease. The clinical trial is on track to begin in the first half of 2024. Initiation of this clinical trial...

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

Written by Customer Service on March 18, 2024. Posted in Public Companies.

TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office (the “Patent”). The Patent aligns seamlessly with the Company’s proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. This patent grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies. Oz Adler, CEO of SciSparc, commented,...

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Written by Customer Service on March 18, 2024. Posted in Public Companies.

British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virusPhase II findings previously disclosed support dipeptidase-1 (DPEP-1) as a relevant therapeutic target for diseases of the lung, kidneys and liver where inflammation plays a major role.New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.TORONTO, March 18, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc.,...

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Written by Customer Service on March 18, 2024. Posted in Earnings Releases And Operating Results.

A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for inflammation and pain following cataract surgery On-track to report topline data from OCS-02 (Licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED) in Q2 2024, OCS-01 Phase 3 OPTIMIZE-2 trial, and OCS-05 proof-of-concept ACUITY trial in Q4 2024 Cash, cash equivalents and short-term investments of $108.9 million funding operations and planned clinical trials, as well as advancements in DIAMOND-1 and DIAMOND-2 Phase 3 trials R&D Day held on February 28, 2024, showcasing OCS-01 DME and OCS-02 DED and their transformative treatment potentialsZUG, Switzerland and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq:...

Rego Payment Architectures, Inc. Announces Major Sponsorship of Annual Q2 Customer Event

Written by Customer Service on March 18, 2024. Posted in Public Companies.

Leading, white-labeled youth banking platform announces its Platinum sponsorship of CONNECT 24, Q2’s annual customer conference. BLUE BELL, Pa., March 18, 2024 (GLOBE NEWSWIRE) — Rego Payment Architectures, Inc. (“REGO”) (OTCQB: RPMT), the leading white-labeled family digital wallet platform provider for financial institutions, today announces its Platinum sponsorship of CONNECT 24, the customer conference for Q2 Holdings, Inc. (NYSE: QTWO), a leading provider of digital transformation solutions for financial services. This year’s CONNECT 24 will be held at the Fairmont Hotel in Austin, TX from June 4 to June 6 of 2024. Over 1300 attendees are expected to attend, including many of Q2’s bank and credit union customers. As mentioned in a previous announcement, REGO’s youth banking platform is integrated with Q2’s Digital Banking...

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Written by Customer Service on March 18, 2024. Posted in Public Companies.

The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacksZUG, Switzerland, March 18, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, presented at two recent congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) and the 2024 HAE International (HAEi) Regional Conference Americas. “We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris....

LiveOne (Nasdaq: LVO) Announces Special March Update

Written by Customer Service on March 18, 2024. Posted in Earnings Releases And Operating Results.

-Reports $11.5 Cash Position, the Largest in 18 Months -Extinguished $3.0M of PodcastOne (Nasdaq: PODC) Payables -Repurchased $250k of Stock in the Past 30 Days   -Repurchased Total $4.5M of LVO Shares -$5.5M Remaining for Discretionary Repurchase of LVO and/or PODC Common Stock -Experiencing Explosive Growth and Expects Record Q4 Revenues Driven by Increased Tesla Sales, 30 New Podcasts and $2M+ New Monthly Recurring Revenues From B2B Fortune 250 Streaming Partner LOS ANGELES, CA, March 18, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – LiveOne CEO Robert Ellin commented, “I am immensely proud of the remarkable achievements of our organization. The hard work, dedication, and passion exhibited by our team has been nothing short of extraordinary. Every division has played an integral role in reaching the milestones we celebrate today.” Mr...

Day: March 18, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice